
Work Here?
Curaleaf is a cannabis company that grows, processes, and sells cannabis products for medical and recreational use. It offers items such as tinctures, flowers, and edibles, and uses encapsulation technology to improve product absorption and effectiveness. Customers can buy at dispensaries or online, and the company also provides medical consultations and guidance services. Differentiators include its vertically integrated model (cultivation, processing, and retail) and its social responsibility efforts, such as the B NOBLE program that supports individuals with cannabis-related non-violent charges. The company’s goal is to provide reliable cannabis products and related services to a wide range of customers while advancing responsible access and advocacy through programs like B NOBLE.
Industries
Social Impact
Biotechnology
Healthcare
Consumer Goods
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wakefield, Massachusetts
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$2.5B
Above
Industry Average
Funded Over
12 Rounds
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
Life Insurance
Disability Insurance
Curaleaf Holdings has issued a letter urging Aurora Cannabis shareholders to accept its takeover offer, which represents a 45% premium over Aurora's 30-day volume weighted average price. The acquisition would create a combined company operating across 17 countries with US$1.5 billion in last twelve-month revenue and nearly US$350 million of adjusted EBITDA. Curaleaf Chairman and CEO Boris Jordan framed the decision starkly, describing Aurora as "a shrinking business that is burning cash and getting less profitable by the day." The company expects at least US$40 million in annual cost synergies from the combination. Aurora has refused to engage with Curaleaf's proposal. Jordan announced a live shareholder Q&A session scheduled for 17 September to discuss the offer directly with Aurora investors.
Curaleaf Holdings has opened a new cannabis dispensary in downtown Boston at 21 Milk St., near Downtown Crossing. The location opened on 4 September, offering patients expanded retail space and a broader selection of products. The dispensary will stock Curaleaf's portfolio of cannabis brands, including Dark Heart, Select, FIND, Anthem and Grassroots. Knowledgeable staff will assist customers in selecting products suited to their needs. A grand opening celebration is scheduled for 8 September, featuring in-store promotions, a Meet the Grower event, and brand activations. The store operates from 09:00 to 20:00 Monday through Saturday, and 09:00 to 18:00 on Sunday. The opening follows the closure of Curaleaf's former Provincetown dispensary.
Curaleaf has formally launched its hostile takeover bid for Aurora Cannabis, offering $4 per share directly to shareholders. The offer represents a 45% premium on Aurora's 30-day average share price from 10 August, before Curaleaf announced its intentions. The proposed deal would create a combined company with a $3 billion market cap. Curaleaf projects approximately $40 million in annual cost synergies from the merger. The acquisition aims to give Curaleaf access to EU medical cannabis export markets, particularly Germany. Aurora possesses EU-GMP cultivation capacity that meets strict German import standards. Federal restrictions make direct cannabis exports challenging for US firms like Curaleaf. Curaleaf CEO Boris Jordan said initial friendly discussions with Aurora CEO Miguel Martin earlier this summer stalled, prompting the direct shareholder approach. Aurora's board has formed a special committee to review the offer.
Curaleaf Holdings reported second quarter 2026 revenue of $340 million, representing 10% year-over-year growth driven by domestic and international segments that grew 7% and 26%, respectively. International revenue reached $51 million. The cannabis company posted net income of $12 million and adjusted EBITDA of $70 million, reflecting a 21% margin. Gross profit margin stood at 50%. Chairman and CEO Boris Jordan said the results demonstrate the company's "Built for Growth" strategy is gaining traction. He noted this marks the second consecutive quarter of domestic year-over-year growth. Curaleaf ended the quarter with $107 million in cash and $611.5 million in outstanding debt. The company invested $32.9 million in capital expenditures during the six-month period, focused on facility upgrades and automation.
Curaleaf Holdings has opened its 75th dispensary in Florida, located in Boynton Beach. The cannabis retailer now operates 167 locations nationwide, with Florida representing nearly half of its retail footprint. The new store at 3575 W. Boynton Beach Boulevard is the company's sixth Florida opening this year. It offers medical cannabis products including Anthem pre-rolls, Dark Heart ultra-premium flower, and Select vaping products. Boris Jordan, chairman and CEO, said the opening reinforces Curaleaf's commitment to expanding access to cannabis products across Florida. A grand opening celebration is scheduled for 31 July and 1 August, featuring special promotions and giveaways. The dispensary operates 9:00 to 20:30 Monday through Saturday, and 10:00 to 18:00 on Sunday.
Find jobs on Simplify and start your career today
Industries
Social Impact
Biotechnology
Healthcare
Consumer Goods
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wakefield, Massachusetts
Founded
2010
Find jobs on Simplify and start your career today